phil bonomi, md, discusses costs of new lung cancer therapies relative to duration of therapy
Published 8 years ago • 56 plays • Length 0:48
Download video MP4
Download video MP3
Similar videos
-
0:50
phil bonomi, md, on importance of checkpoint inhibitors in first-line nsclc setting
-
0:41
phil bonomi, md, offers opinion on whether met inhibitors are effective in metastatic nsclc
-
2:01
phil bonomi, md, on immunotherapy for treatment of sclc and mesothelioma
-
3:32
gracecastuc102_kidney_dr. bonomi on targeted therapy toxicity chemotherapy
-
2:44
david berz, md, phd, and philip bonomi, md discuss molecular diagnostics in nsclc
-
2:22
gracecastuc-032_lung_dr. bonomi - maint. therapy after first line chemo a mandate, option, neither?
-
0:35
phil bonomi, md, talks about the evolving role of targeted agents in 2nd line nsclc and beyond
-
2:30
gracecastuc088_lung_dr. bonomi on lung cancer targeted therapies
-
2:12
gracecastuc-078_lung_dr. bonomi on most promising new targeted agents and molecular pathways for lc
-
3:34
david berz, md, phd, and philip bonomi, md discuss use of liquid biopsies over surgical biopsies
-
1:28
dr. phillip bonomi - treatment of squamous cell lung cancer - jan. 24, 2017
-
0:52
dr. phil bonomi: recommending a repeat biopsy with acquired resistance to a targeted therapy
-
1:21
david berz, md, phd, and philip bonomi, md discuss liquid biopsies versus tissue biopsies
-
1:01
dr. philip bonomi: gefitinib and later generations of egfr inhibitors
-
2:27
david berz, md, phd, and philip bonomi, md discuss benefits of urine-based mutational screening
-
50:50
management of lung cancer in 2017
-
1:54
balancing the benefits and costs of immunotherapy in the treatment of lung cancer
-
18:58
lung cancer: mayo clinic radio
-
7:32
#wclc# interview with prof. philip bonomi: immunotherapy is the future of cancer therapy
Clip.africa.com - Privacy-policy